Saturday, June 13, 2026

Seasonal #vaccine-induced #immunity shows preserved cross-reactivity to #H3N2 subclade K in adults

 


Summary

Background

Influenza A subclade K viruses caused high infection rates in the 2025/2026 Northern Hemisphere season, raising concerns about antigenic drift and reduced vaccine effectiveness.

Methods

We measured antibody responses in matched human pre- and post-vaccination sera, selected from two observational cohort studies of adults, against both a vaccine-like as well as subclade K isolates.

Findings

Pre-existing immunity to subclade K variants was noted with seasonal influenza vaccination further boosting titres two-fold against subclade K and three-fold against the vaccine-like strain, consistent with limited antigenic divergence between subclade K isolates and the vaccine. These findings contrast with ferret-based predictions of marked antigenic drift and align with the observed vaccine effectiveness in adults.

Interpretation

Our results underscore the importance of incorporating human serologic data in influenza surveillance to better inform vaccine strain selection and anticipate vaccine performance in immunologically experienced populations.

Funding

NIAID Centers for Excellence in Influenza Research and Response (75N93021C00014); NIAID VIVA HIPC (U19 AI168631); Mount Sinai Center for Vaccine Research and Pandemic Preparedness; institutional support from the Mount Sinai Center for Vaccine Research and Pandemic Preparedness and the Medical University of Vienna.

Source: 


Link: https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(26)00203-3/fulltext

____

History of Mass Transportation: The Class 88 Diesel Shunter of Romanian Railways

 


{Click on Image to Enlarge}

By Stefan Puscasu - http://cfr.stfp.net/?sta=1&class=88&ppr=5, Public Domain, https://commons.wikimedia.org/w/index.php?curid=8459468

Source: 


Link: https://en.wikipedia.org/wiki/Rolling_stock_of_the_Romanian_Railways#/media/File:Locomotiva_CFR_clasa_88.jpg

____

#Coronavirus Disease Research #References (AMEDEO, June 13 '26)

 


    Clin Infect Dis

  1. BRITT NS, Khader K, He T, Prinzi AM, et al
    Clinical Impact of the BIOFIRE(R) FILMARRAY(R) Pneumonia Panel in the Veterans Affairs Healthcare System: A Difference-in-Differences Study.
    Clin Infect Dis. 2026 Jun 12:ciag328. doi: 10.1093.
    PubMed         Abstract available


    Infect Control Hosp Epidemiol

  2. NERBY J, Berg W, McFarren M, Rhame F, et al
    Collaborative approaches to masking: statewide threshold development and performance across three respiratory seasons.
    Infect Control Hosp Epidemiol. 2026 Jun 11:1-7. doi: 10.1017/ice.2026.10487.
    PubMed         Abstract available


    Int J Infect Dis

  3. CHEN H, Manu EK
    Shifting patterns of acute respiratory infection mortality in Australia: Changing contributions of COVID-19, influenza and respiratory syncytial virus and persistent Indigenous inequalities.
    Int J Infect Dis. 2026 Jun 8:108866. doi: 10.1016/j.ijid.2026.108866.
    PubMed         Abstract available


    Intensive Care Med

  4. MEYBOHM P, Baron DM, Fries D, Lasocki S, et al
    Patient blood management in general intensive care patients.
    Intensive Care Med. 2026 Jun 8. doi: 10.1007/s00134-026-08491.
    PubMed         Abstract available


    J Infect

  5. HARRIS R, Thirard R, McBrien C, Middleditch A, et al
    Immunogenicity and safety of co-administration of a recombinant shingles vaccine with an mRNA COVID-19 or adjuvanted influenza vaccine: a randomised controlled trial.
    J Infect. 2026 Jun 4:106784. doi: 10.1016/j.jinf.2026.106784.
    PubMed         Abstract available

  6. WANG X, Yin J, Xu B, Guanhua X, et al
    Clinical epidemiological characteristics of hospitalized pediatric Mycoplasma pneumoniae pneumonia in China.
    J Infect. 2026 Jun 10:106793. doi: 10.1016/j.jinf.2026.106793.
    PubMed         Abstract available

  7. TRUONG T, Radin JM, Li L, Ordonez-Mena JM, et al
    Burden and economic impact of RSV hospitalisations among English adults, 2023/24.
    J Infect. 2026;93:106792.
    PubMed         Abstract available


    J Med Virol

  8. USHIJIMA H, Onda-Shimizu Y, Kotaki T, Nishimura S, et al
    Co-Circulation and Mixed Infections of Classic and Melbourne Human Astroviruses Among Pediatric Acute Gastroenteritis Patients in Japan, 2018-2024.
    J Med Virol. 2026;98:e71002.
    PubMed         Abstract available

  9. AYDIN U, Duzenci D, Akkoc RF, Karatas A, et al
    Serum Histatin Levels in COVID-19: Association With Disease Severity and Immune Status.
    J Med Virol. 2026;98:e71009.
    PubMed         Abstract available

  10. CHEN R, Kong W, Li C, Zhang J, et al
    TXD-198 Exhibits Inhibitory Activity Against SARS-CoV-2 by Upregulating ANO1.
    J Med Virol. 2026;98:e71004.
    PubMed         Abstract available

  11. DENG J, Lin Q, Zeng Z, Huang H, et al
    Post-Pandemic Influenza Resurgence in Guangzhou, China: Impact of COVID-19 Interventions and Immune Alterations.
    J Med Virol. 2026;98:e71012.
    PubMed         Abstract available

  12. FU JYL, Lim SK, Jalalonmuhali M, Bador MK, et al
    Immune Pressure From Plasma From Immunocompromised and Healthy Individuals Drives Differential SARS-CoV-2 Evolution and Escape Mutation Emergence.
    J Med Virol. 2026;98:e71016.
    PubMed         Abstract available


    J Travel Med

  13. LUBBERT C, Fruhwein M, Dinjer CS, Machler C, et al
    Assessment of the healthcare burden of dengue disease in Germany: a retrospective analysis of statutory health insurance data (2014-2023).
    J Travel Med. 2026 Jun 11:taag047. doi: 10.1093.
    PubMed         Abstract available


    J Virol

  14. YANG Y, Su Z, Zhang X, Tan Y, et al
    PPP2R5B regulates ANPEP expression and TGEV entry via dephosphorylation of HSF1 at Ser304/Ser308.
    J Virol. 2026 Jun 11:e0016626. doi: 10.1128/jvi.00166.
    PubMed         Abstract available

  15. YO MS, Kaku Y, Kosugi Y, Tolentino JE, et al
    Genetic diversity of pangolin coronaviruses reveals a key immuno-evasive substitution at spike residue 519.
    J Virol. 2026 Jun 10:e0035226. doi: 10.1128/jvi.00352.
    PubMed         Abstract available

  16. PENG M, Liu L, Li X, Yu X, et al
    Pre-pandemic contraction, phase-specific rate variation, and site-specific antigenic adaptation shape influenza A(H3N2) evolutionary dynamics in Hubei, China.
    J Virol. 2026 Jun 10:e0055626. doi: 10.1128/jvi.00556.
    PubMed         Abstract available

  17. ARTUSA V, Limanaqi F, Santacroce E, Clerici M, et al
    Alpha-synuclein at the crossroads of host-virus interactions: immunological roles beyond the nervous system.
    J Virol. 2026 Jun 9:e0019126. doi: 10.1128/jvi.00191.
    PubMed         Abstract available

  18. VARGAS DA, Albornoz LL, Pena-Morales M, Ortiz Rojas HJ, et al
    Within-host SARS-CoV-2 diversity in immunocompromised patients during acute infection.
    J Virol. 2026 Jun 9:e0222425. doi: 10.1128/jvi.02224.
    PubMed         Abstract available

  19. YU H-M, Zhu M-L, Zhao Y-L, Tan J-X, et al
    Research progress on the association between viruses and cardiac diseases.
    J Virol. 2026 Jun 9:e0038326. doi: 10.1128/jvi.00383.
    PubMed         Abstract available

  20. LI S, Luo H, Zhang K, Wu C, et al
    The cholesterol transporter Niemann-Pick C1 facilitates the entry of porcine epidemic diarrhea coronavirus.
    J Virol. 2026 Jun 9:e0030126. doi: 10.1128/jvi.00301.
    PubMed         Abstract available

  21. ZHANG Q, Xin J, Wang C, Zhang X, et al
    Cleavage of TOM1 by the SARS-CoV-2 main protease NSP5 prevents autophagic degradation of viral envelope.
    J Virol. 2026 Jun 12:e0043426. doi: 10.1128/jvi.00434.
    PubMed         Abstract available


    Lancet Infect Dis

  22. XIE Y, Choi T, Al-Aly Z
    Seasonal influenza versus COVID-19 hospitalisation risk during the 2025-26 influenza season.
    Lancet Infect Dis. 2026 Jun 10:S1473-3099(26)00289.
    PubMed        


    Travel Med Infect Dis

  23. MIHAI I, Bonnaud L, Arregle F, Doudier B, et al
    Purulent meningococcal pericarditis with cardiac tamponade in a Hajj pilgrim: A diagnostic challenge of anchoring bias on MERS-CoV.
    Travel Med Infect Dis. 2026;72:103001.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, June 13 '26)

 


    Arch Virol

  1. SMATTI MK, Al-Khatib H, Suleman M, Nizar M, et al
    Functional and structural characterization of the SARS-CoV-2 spike N481K mutation.
    Arch Virol. 2026;171:198.
    PubMed         Abstract available


    J Infect

  2. HARRIS R, Thirard R, McBrien C, Middleditch A, et al
    Immunogenicity and safety of co-administration of a recombinant shingles vaccine with an mRNA COVID-19 or adjuvanted influenza vaccine: a randomised controlled trial.
    J Infect. 2026 Jun 4:106784. doi: 10.1016/j.jinf.2026.106784.
    PubMed         Abstract available

  3. CORRAO G, Sguazzini E, Gori A, Monti E, et al
    All-cause mortality within seven days of COVID-19 vaccination: A matched cohort and self-controlled case series study in Lombardy, Italy.
    J Infect. 2026;93:106769.
    PubMed         Abstract available

  4. GUINOVART LJ, Westrhenen SEMH, Schuurman R, Bruijning-Verhagen PCJL, et al
    Symptomatology of SARS-CoV-2 versus seasonal coronavirus infection in healthy young children.
    J Infect. 2026 May 20:106762. doi: 10.1016/j.jinf.2026.106762.
    PubMed         Abstract available


    J Infect Dis

  5. LIU F, Gross FL, Li Z, House SL, et al
    Birth cohort effects in adults associated with influenza A(H1N1)pdm09 vaccine effectiveness.
    J Infect Dis. 2026 Jun 8:jiag294. doi: 10.1093.
    PubMed         Abstract available


    J Virol

  6. LIU Z, Fan M, Zeng Y, Zheng Y, et al
    Gga-miR-92-targeted TNFRSF1B inhibits the replication of influenza A virus by degrading TRAF3.
    J Virol. 2026 Jun 12:e0067426. doi: 10.1128/jvi.00674.
    PubMed         Abstract available

  7. XU S, Zhang Q, Xie X, Zhou M, et al
    A neutralizing nanobody targeting a conserved lateral patch on HA1 confers protection against multiple H7 avian influenza viruses.
    J Virol. 2026 Jun 11:e0056326. doi: 10.1128/jvi.00563.
    PubMed         Abstract available

  8. PENG M, Liu L, Li X, Yu X, et al
    Pre-pandemic contraction, phase-specific rate variation, and site-specific antigenic adaptation shape influenza A(H3N2) evolutionary dynamics in Hubei, China.
    J Virol. 2026 Jun 10:e0055626. doi: 10.1128/jvi.00556.
    PubMed         Abstract available


    PLoS Comput Biol

  9. LIN Z, Gao Y, Sun W
    Supervised deep learning with gene functional annotation for cell classification.
    PLoS Comput Biol. 2026;22:e1014327.
    PubMed         Abstract available

  10. KWON J, Li K, Warren JL, Pandya S, et al
    Utilizing virus genomic surveillance to predict vaccine effectiveness.
    PLoS Comput Biol. 2026;22:e1014329.
    PubMed         Abstract available


    PLoS One

  11. TAM VCW, Yeung NCY, Kwok AWL
    Getting over the hurdles to save lives: Incorporating perceived barriers into theory of planned behaviour (TPB) model to predict stated intention among Hong Kong trained laymen.
    PLoS One. 2026;21:e0350392.
    PubMed         Abstract available

  12. KONDO K, Morita I, Sakuma S, Ohsawa I, et al
    Changes in tobacco sales before, during, and after the COVID-19 pandemic in Japan: An interrupted time series analysis.
    PLoS One. 2026;21:e0350820.
    PubMed         Abstract available

  13. WOODGATE RL, Mary-Quigley L, Bell A, Bennett M, et al
    Youth's mental health journeys through the COVID-19 pandemic using arts-based methods in virtual environments.
    PLoS One. 2026;21:e0349860.
    PubMed         Abstract available

  14. KARAMI B, Rezaeian S, Bagherinia M, Shakiba E, et al
    Social support and health related quality of life among older people in covid-19 pandemic: The mediating role of resilience.
    PLoS One. 2026;21:e0342982.
    PubMed         Abstract available

  15. YANG RJ, Wang M, Lyu L, You JL, et al
    Pathogen spectrum and epidemiology of respiratory tract infections in Quzhou, Eastern China, from November 2023 to July 2024: A post?COVID?19 surveillance study.
    PLoS One. 2026;21:e0346441.
    PubMed         Abstract available

  16. BOLSHOV O, Chumachenko D
    Reinforcement learning for policymaking in epidemic control: A scoping review.
    PLoS One. 2026;21:e0351176.
    PubMed         Abstract available

  17. LIU C, Liu H, Wei Y, Ye J, et al
    Modeling the effects of meteorological factors and media-driven public awareness on seasonal influenza outbreaks.
    PLoS One. 2026;21:e0342962.
    PubMed         Abstract available

  18. LIU F, Lai T, Xu W, Li G, et al
    ViralMultiNet: A structure-aware multimodal framework for viral protein function prediction in wastewater surveillance.
    PLoS One. 2026;21:e0349393.
    PubMed         Abstract available

  19. MOUNCHID PM, Shukla S, Steinert JI
    The interplay of economic shocks and cultural practices in child marriage: Comparative evidence from India and Zambia during the COVID-19 pandemic.
    PLoS One. 2026;21:e0346851.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  20. ZHU Z, Fragkias M, Suh JW, McCoshan E, et al
    The Urban Pulse: Diagnosing the urbanization process as spiky, cyclical, and asynchronous.
    Proc Natl Acad Sci U S A. 2026;123:e2537770123.
    PubMed         Abstract available

  21. SKELLY AN, Fan C, Keeffe JR, Okten AB, et al
    mRNA delivery of a class 1/4 SARS-CoV-2 neutralizing antibody protects against diverse sarbecoviruses in a lethal mouse challenge model.
    Proc Natl Acad Sci U S A. 2026;123:e2536870123.
    PubMed         Abstract available


    Vaccine

  22. WU X, Tao Y, Sun Y, Chen J, et al
    Cost-effectiveness of free influenza vaccination policy for Chinese older adults: a modeling analysis using real-world data.
    Vaccine. 2026;88:128782.
    PubMed         Abstract available

  23. BIETZ A, Sandow P, Hartmann C, Steffan L, et al
    Real-time in-season monitoring of adult influenza vaccination coverage rates in Germany: results from a repeated cross-sectional online survey.
    Vaccine. 2026;88:128765.
    PubMed         Abstract available

  24. SONG L, He G, Cui Y, Tan R, et al
    Optimized flagellin enhances systemic and mucosal immune responses induced by SARS-CoV-2 virus-like particle vaccines.
    Vaccine. 2026;87:128767.
    PubMed         Abstract available

  25. FAIJUE DD, Bouaddi O, Segui AO, Morias B, et al
    Catch-up and life-course vaccination policies for adult and adolescent migrants in low-and-middle income countries: A policy analysis.
    Vaccine. 2026;85:128645.
    PubMed         Abstract available

  26. FORNS J, Pajouheshnia R, Aurelius T, Bouck Z, et al
    Risk of thrombosis with thrombocytopaenia syndrome (TTS) after vaccination with AZD1222: a European VAC4EU post-authorisation safety study.
    Vaccine. 2026;86:128723.
    PubMed         Abstract available

  27. POWELL A, Suwalowska H, Sankoh O, Guo C, et al
    Recent enough to matter: Perceived temporal proximity, anxiety, and COVID-19 vaccine intent.
    Vaccine. 2026;85:128717.
    PubMed         Abstract available

  28. DALEXIS RD, Beogo I, Kibret TC, Cenat JM, et al
    Racial disparities in coverage and determinants of childhood diphtheria, tetanus, and pertussis (DTaP) vaccination in Canada: a post-COVID-19 pandemic analysis.
    Vaccine. 2026;85:128679.
    PubMed         Abstract available

  29. KOIRALA A, Prasad SA, Tjiam MC, Britton PN, et al
    SARS-CoV-2 Ancestral and Omicron variant immunity in Australian children in 2023, a seroprevalence study.
    Vaccine. 2026;85:128705.
    PubMed         Abstract available

  30. XU Y, Nyberg F, Marking U, Gisslen M, et al
    Rare adverse events after COVID-19 vaccination among Swedish older adults-evidence from a nationwide register-based study.
    Vaccine. 2026;85:128724.
    PubMed         Abstract available

  31. DANCHIN M, Rak A, Vasiliadis S, Wang B, et al
    Maternal preferences for infant respiratory syncytial virus (RSV) preventives: an Australian discrete choice experiment.
    Vaccine. 2026;85:128710.
    PubMed         Abstract available

  32. KOHLI M, Maschio M, Lee A, Kissler S, et al
    The cost-effectiveness of vaccination against COVID-19 in at-risk populations and older adults in the United Kingdom: Projections using a dynamic transmission model.
    Vaccine. 2026;85:128687.
    PubMed         Abstract available

  33. TRANG TPH, Bazelier MT, Klungel OH, Bots SH, et al
    Quality and methodological heterogeneity of COVID-19 vaccine safety studies focusing on the myocarditis safety signal: A systematic review, meta-analysis and meta-regression.
    Vaccine. 2026;85:128722.
    PubMed         Abstract available

  34. WANG R, Zhao Y, Yang J, Luo R, et al
    Systemic BCG administration induces transcription factor signature in CD4(+) T cells that cooperates with IL-12 signaling to drive antiviral Th1 differentiation.
    Vaccine. 2026;85:128720.
    PubMed         Abstract available


    Virology

  35. KOVACS E, Rios Carrasco M, Guerreiro Cabana MF, de Vries RP, et al
    H5N1 2.3.4.4b HA E190D and Q226H mutations, picked up as minority variants in a patient, result in an inability to bind sialic acid.
    Virology. 2026;621:110949.
    PubMed         Abstract available


    Virus Res

  36. TJARNHAGE E, Vatsveen TK, Raki M, Nemazee D, et al
    Repurposing ALK Inhibitors as Influenza and Corona Virus Antivirals Targeting Lymphocyte Tyrosine Kinase (LTK).
    Virus Res. 2026 Jun 9:199759. doi: 10.1016/j.virusres.2026.199759.
    PubMed         Abstract available

Friday, June 12, 2026

#Incubation and infectious period, asymptomatic or presymptomatic #transmission and transmission route in #human-to-human spread of #hantavirus #infection (UKHSA, summary)


 

{Summary)

Main messages 

    1. This systematic evidence summary (search up 1 May 2026) identified and summarised evidence relating to the incubation and infectious period, asymptomatic or presymptomatic transmission and transmission route in human-to-human transmission of hantavirus infection.  

    2. Human-to-human transmission was only reported for Andes virus.  

    3. Seventeen studies were identified to include (1 to 17). All studies were from South America (Argentina, Chile, Paraguay or Uruguay) from 1995 to 2024. Three sets of studies clearly reported on the same outbreak.  

    4. Seven studies reported the incubation period, or enough information to calculate the incubation period of Andes virus (4, 6, 8, 10, 12, 13, 15, 17). Four of these reported overlapping evidence, (4, 8, 12, 17) leaving 5 independent reports. The reported incubation period ranged from 9 to 40 days, with studies reporting a mean between 21.6 to 27.5 days.   

    5. Three studies reporting incubation period included children (6, 10, 12). When evidence for children was separated, the range was 14 to 26 days. The mean (and standard deviation, SD) from one study with data to calculate it was 19.8 days (3.7) in children and 21.9 days (7.4) in adults (12). The available evidence was insufficient to determine if there was a significant difference between adults and children and not all studies separated the results.   

    6. Twelve studies reported the serial interval or enough information to calculate the serial interval of Andes virus (1, 2, 5, 9 to 14, 16, 17). Four of these reported overlapping evidence,(10, 11, 14, 17) leaving 10 independent reports. The reported serial interval ranged from 4 to 40 days with means across studies from 19.6 to 25.7 days.  

    7. Six studies reporting serial interval included children (2, 5, 9, 10, 12, 16). When evidence for children was separated, the range was 16 to 29 days. The mean (and SD) from one study with data to calculate it was 19.7 (3.5) in children and 19.5 (8.1) in adults. The available evidence was insufficient to determine if there was a significant difference between adults and children and not all studies separated the results.  

    8. None of the studies reported confirmed route of transmission. Some hypothesised routes from exposures including the possibility of respiratory, direct contact via breastfeeding, other direct contact and sexual transmission. None ruled out respiratory or fomite transmission alongside other possible routes.  

    9. No studies reported evidence of asymptomatic or presymptomatic transmission. 

    10. Most studies included groups identified as being at risk of health inequalities, including children, pregnant women, people living in rural settings and people in occupations at higher risk of exposure such as agricultural workers or farmers and people working in healthcare settings. However, none of the studies provided a comparison between groups and it was not possible to determine if outcomes differed in these groups. 

    11. Critical appraisal was not performed, which restricts the interpretation of the findings, but important limitations have been highlighted. There were a limited number of cases with likely human-to-human transmission which limits the generalisability of the evidence. Many studies also highlighted the possibility than some of these cases also had environmental exposure, although human-to-human transmission was most likely. All studies rely on selfreport of exposure and symptom onset dates, which may be subject to recall bias or misreporting. There was also discrepancy between some studies reporting on the same cases, which highlights the likelihood of misreporting of this evidence.  

    12. In summary, there was evidence from a limited number of cases to provide information of the incubation period and serial interval for human-to-human transmission of Andes virus. There was no information available that directly informed the infectious period in humans. Evidence suggested incubation period could range from 9 to 40 days, with studies reporting a mean between 21.6 to 27.5 days. The reported serial interval ranged from 4 to 40 days with means from 19.6 to 25.7 days. Although no studies were able to confirm route of transmission, some proposed routes through exposures, including the possibility of direct contact via breast-feeding, and sexual transmission or contact. No studies reported evidence of asymptomatic or presymptomatic transmission. All of the evidence is at risk of bias from misreport or recall bias, possible environmental exposure and ability to generalise due to small numbers of cases. 

(...)

Source: 


Link: https://www.gov.uk/government/publications/hantavirus-human-to-human-infection-transmission-parameters

____

#HK PRC SAR, CHP investigates a #human case of #influenza #H9 #infection (June 12 '26)

 


    The Centre for Health Protection (CHP) of the Department of Health (DH) is today (June 12) investigating a case of human infection with influenza A (H9) in collaboration with relevant departments. 

    The patient is a two-year-old boy. His condition has remained mild and he is currently in stable condition

    The CHP will send a letter to all doctors in Hong Kong to update them on the latest developments regarding avian influenza A and to urge them to remain vigilant and report any suspected cases.

 

Case information

    The boy lives in Sha Tin District. He developed a fever and mild diarrhoea on June 9. On the following day (June 10), he was brought to Prince of Wales Hospital and was admitted for treatment. His clinical specimen tested positive for the influenza A (H9) virus by the Public Health Laboratory Services Branch (PHLSB) of the CHP. The subtyping result is pending. His clinical diagnosis was novel influenza. He is currently in stable condition and has been admitted to an isolation ward at Princess Margaret Hospital for treatment.

      The CHP's preliminary investigation revealed that the patient had no travel history during the incubation period. 

    The case has been classified as a locally acquired case. 

    The patient does not attend school or receive daycare services. 

    He is primarily cared for by his family members and spends most of his time at home or nearby. 

    His household does not keep poultry

    According to information provided by his family members, he has neither consumed undercooked poultry nor come into contact with any patients

    In early June, one of his family members took him to Wo Che Market on two occasions. During these visits, the patient stayed at a fresh provision shop in the market that sells live chickens to watch the poultry and touched the surroundings of the fresh provision shop

    The CHP conducted an investigation with the Food and Environmental Hygiene Department (FEHD) and collected environmental samples from the shop concerned. 

    The shop staff remained asymptomatic

    The patient has six household contacts and they remain asymptomatic so far. 

    The CHP has provided them with preventive medication and put them under medical surveillance.

      The CHP is continuing to investigate the source of infection of the case and is conducting whole genome sequencing of the virus sample. The CHP will also report the case to the World Health Organization (WHO).

      Humans are primarily infected with the influenza A virus through direct contact with infected poultry or through indirect contact with environments contaminated by their droppings. 

    The CHP's epidemiological investigation indicated that the patient had visited a location where live poultry was sold. It cannot be ruled out that the patient was infected through indirect contact with a contaminated environment at the wet market. 

    As young children have weaker immune systems and are incapable of maintaining good hand hygiene, the CHP advised parents to avoid taking young children to places where live poultry is sold. 

    Transporting poultry may contaminate the ground and the surrounding environment. 

    As young children are shorter in height and easy to be in contact with the surrounding environment, they are at greater risk of coming into contact with poultry droppings or contaminated areas.

      In the past ten years, the WHO has received reports of a total of over 160 cases of human infection with influenza A (H9) worldwide

    To date, most case of human infection with influenza A (H9) have presented with only mild clinical illness

    According to the WHO's risk assessment, the influenza A (H9) virus has not acquired the ability for sustained human-to-human transmissions.

 

Government's comprehensive follow-up actions

    Novel influenza A infection, including influenza A (H9), is a notifiable infectious disease in Hong Kong

    Compared to other highly pathogenic avian influenza strains such as H5N1 and H7N9, influenza A (H9) is a low-pathogenic avian influenza strain that causes milder illness

    Excluding the aforementioned case, 10 cases of influenza A (H9N2) have been reported since 1999, including four locally acquired cases and six imported cases

    No deaths have been recorded so far. 

    In response to the latest local case, the CHP will issue a letter to all doctors in Hong Kong, reminding them of the latest situation of influenza A (H9), and urging them to remain vigilant and report any suspected cases.

      Sporadic cases of human infection with avian influenza occur from time to time internationally. Although the current risk of an outbreak is low, the Hong Kong Special Administrative Region Government has consistently implemented preventive measures, including a disease surveillance system, the implementation of livestock control measures at farms, markets and ports, in order to prevent avian influenza.

      The PHLSB of the CHP comprises laboratories with high biosafety standards, capable of conducting, testing for high-risk pathogens, and which also possess sufficient testing and genetic analysis capabilities and facilities. Hong Kong currently has sufficient reserve of antiviral medications.

 

Preventive measures to be taken by the public

    Humans are primarily infected with the avian influenza A virus through contact with infected birds, poultry or other animals (whether alive or dead), or through surfaces or environments contaminated with saliva, mucous and animal faeces (such as wet markets and live poultry markets). 

    The virus has very low transmissibility among humans. People who have close contact with live poultry are more susceptible to contracting avian influenza. The elderly, children and people with chronic illnesses have a higher risk of developing complications such as bronchitis and pneumonia, if infected. 

    Members of the public should remain vigilant and take the following measures to prevent avian influenza:

         ° Avoid contact with poultry, birds or their droppings. If contact has been made, thoroughly wash hands with soap and water;

        ° Poultry and eggs should be thoroughly cooked before eating;

        ° Perform hand hygiene at all times, especially before touching the mouth, nose or eyes; after contact with animals or their living environments; after touching public installations such as handrails or doorknobs; or when hands are contaminated with respiratory secretions, such as after coughing or sneezing;

        ° Cover the mouth and nose with tissue paper when sneezing or coughing. Dispose of soiled tissues into a lidded rubbish bin, then wash hands thoroughly;

        ° When having respiratory symptoms, wear a surgical mask, do not go to work or school, avoid crowded places and seek medical advice promptly;

        ° Avoid crowded public places or areas with poorly ventilated; high-risk individuals may consider putting on a surgical mask when staying in such places; and

        ° Travellers returning to Hong Kong from areas affected by avian influenza outbreaks should consult doctors promptly if they have flu-like symptoms, and inform the doctor of the recent travel history and wear a surgical mask to help prevent spreading of the disease.

    The public may visit the CHP's webpages for more information: Avian Influenza Webpage, Avian Influenza Report, Avian influenza statistics and affected areas around the world, Facebook page and Youtube channel. 

 

Ends/Friday, June 12, 2026 | Issued at HKT 22:19 | NNNN

Source: 


Link: https://www.info.gov.hk/gia/general/202606/12/P2026061200852.htm?fontSize=1

____

Twenty-one #countries launch coordinated #Andes virus #research initiative following #hantavirus #outbreak (WHO, June 12 '26)

 


    Following the recent Andes virus (ANDV) outbreak linked to the MV Hondius cruise ship, a globally coordinated outbreak research initiative involving investigators and institutions across 21 countries has begun implementation,  demonstrating how international research preparedness systems can be rapidly activated during health emergencies.

    The initiative, known as NAVIS, is a natural history study designed to improve understanding of ANDV transmission dynamics, incubation periods, immune responses, viral kinetics, and determinants of severe disease through harmonized longitudinal follow-up of exposed individuals.

    The study will use a harmonized prospective protocol, which was developed by Hospital Germans Trias i Pujol, Badalona, Spain, for immediate deployment after an emergency scientific consultation coordinated through the UK Health Security Agency (UKHSA)-led Hantavirus Collaborative Open Research Consortium (CORC) mobilized more than 1600 experts from over 130 countries to identify urgent scientific priorities and coordinate international research activities.

    “Closing gaps in our scientific knowledge is key to the development of medical countermeasures, and through international coordination we ensure this is accelerated. Preparedness, therefore, must include the ability to rapidly generate scientific evidence during outbreaks, not only respond to them,” said Yper Hall of the UKHSA.

    By using standardized approaches across countries, NAVIS aims to generate comparable datasets to better understand the pathogen and inform the development of medical countermeasures like tests, treatments and vaccines.

    Coordination of the NAVIS platform is being supported by ANRS Emerging Infectious Diseases (ANRS-MIE) under BE READY, a EU-funded global initiative to strengthen research preparedness and rapid scientific mobilization for future epidemics and pandemics. The study will use ISARIC (International Severe Acute Respiratory and Emerging Infection Consortium), an adaptable research framework designed to enable rapid, standardized data and sample collection during emerging infectious disease outbreaks.

    Participating countries include: 

    ° Australia, 

    ° Belgium, 

    ° Canada, 

    ° Democratic Republic of the Congo, 

    ° Denmark, 

    ° France, 

    ° Germany, 

    ° Greece, 

    ° Ireland, 

    ° Italy, 

    ° Japan, 

    ° the Netherlands, 

    ° New Zealand, 

    ° Singapore, 

    ° South Africa, 

    ° Spain, 

    ° Switzerland, 

    ° TĂ¼rkiye, 

    ° the United Kingdom and 

    ° the United States.

    Participating institutions include leading infectious disease, clinical research, and public health centres such as the Australian Centre for Disease Control, Sinai Health System, Institut National de la Recherche MĂ©dicale (Inserm), Hellenic Pasteur Institute, University College Dublin, National Centre for Infectious Diseases, University Hospital Zurich, University of Liverpool, and Emory University, among others.

    “The rapid launch of NAVIS across 21 countries shows what is possible when research networks are established before outbreaks occur,” commented Yazdan Yazdanpanah of ANRS-MIE.

    NAVIS represents a practical example of outbreak research preparedness under the World Health Organization’s R&D Blueprint, which establishes research networks for pathogen families, to support rapid scientific coordination and implementation of outbreak research before emergencies emerge.

    Outbreaks such as that of the ANDV present rare opportunities for scientific investigation, with a limited window of time for generating robust evidence. Without rapid coordination and harmonized protocols, opportunities to better understand the pathogen can be lost.

    “Scientific evidence generation during outbreaks must become operational, coordinated, and immediately deployable. Future outbreak responses should begin by activating research systems that already exist rather than trying to build them during crises,” said Sylvie Briand, Chief Scientist at WHO.

    The initiative also highlights the importance of geographically-distributed research preparedness. Countries and regions where outbreaks emerge or pathogens circulate must be central participants in evidence generation through strengthened clinical trial networks, national ethics committees, laboratory systems, surveillance platforms, and outbreak research infrastructure.

    The ANDV outbreak demonstrated the importance of research preparedness. Future outbreak responses should no longer begin by building research systems during crises. They should begin by activating systems that already exist.

Source: 




____

#USA, #Wastewater Data for Avian #Influenza #H5 (CDC, June 12 '26)

 


{Excerpt}

(...)

Time Period: May 31, 2026 - June 06, 2026

    -- A(H5) Detection3 site(s) (0.7%)

    -- No Detection440 site(s) (99.3%)

    -- No samples52 site(s)


{Click on Image to Enlarge}



(...)

Source: 


Link: https://www.cdc.gov/wastewater/emerging-viruses/h5.html?

____

#Surveillance of West Nile Virus #WNV #infections in #human in #Europe, Weekly Report (ECDC, June 12 '26)

 


Week 24, 2026

Produced on 11 June 2026 at 08:15 based on data submitted up to 10 June 2026


Epidemiological summary

    Since the beginning of 2026, and as of 10 June, 1 country in Europe reported 1 human case of West Nile virus infection: North Macedonia.

    The current report in Table 1 includes the number of probable and confirmed cases of WNV infections per NUTS3 region. However, these figures are preliminary and should be interpreted with caution as they may be revised by the countries as more information becomes available. Consequently, no totals are provided. For further details on case numbers, please refer to the joint monthly report, which offers a more detailed analysis.

    Please note: The table and map in this report contain countries and areas where human West Nile virus infection cases were reported to EpiPulse Cases.


Introduction

    The European Centre for Disease Prevention and Control (ECDC) provides a weekly overview of human cases of West Nile virus (WNV) infection to support the competent authorities responsible for blood safety. This overview can aid decisions on the deferral or testing of blood donors who may have been exposed to the virus, in accordance with Commission Directives 2004/33/EC and 2014/110/EU.

    West Nile virus infection in humans is a notifiable disease at the EU level and cases are reported in accordance with the EU case definition. The table and map in this report show the countries and areas where human cases of WNV infection have been reported to the European surveillance portal for infectious diseases (EpiPulse Cases).

    More information on the occurrence of WNV infection among humans in Europe, as well as WNV outbreaks among equids and birds, is available in the joint monthly report produced by ECDC and the European Food Safety Authority (EFSA).

    Here we present the weekly report as of 10 June 2026.


Overview of West Nile virus cases in EU/EEA and EU-neighbouring countries

{Country - Affected Region - Probable - Confirmed - Total Cases}

    ° North Macedonia - Vardarski - 0 - 1 - 1

(...)

Source: 


____

A neutralizing #nanobody targeting a conserved lateral patch on HA1 confers #protection against multiple #H7 avian #influenza viruses

 


ABSTRACT

Human infections with H7 avian influenza viruses (AIVs) have been documented globally, involving multiple subtypes and geographic regions. However, effective therapeutics targeting H7 influenza viruses remain limited. Here, a panel of nanobodies targeting the HA1 domain of hemagglutinin (HA) was identified by yeast two-hybrid (Y2H) screening, and six candidates were subsequently validated to exhibit hemagglutination inhibition (HI) activity. Of these, a subset also displayed virus microneutralization (MN) activity, while all showed binding activity in ELISA assays. Among them, Nb74 exhibited inhibitory activity against four Chinese recombinant vaccine-matched strains (Rv1–Rv4), which were generated based on the HA sequences of the corresponding inactivated vaccine strains H7-Re1 to H7-Re4. The HI-IC50 values were 0.23, 0.57, 3.65, and 43.75 µg/mL, respectively, and the MN-IC50 values for Rv1–Rv3 were 0.02, 0.06, and 1.09 µg/mL. It also retained activity against diverse clinical isolates although HI potency varied among strains. In mouse challenge experiments, intratracheal administration of Nb74 conferred robust protection, achieving 100% and 80% survival against Rv1 and Rv2, respectively, when administered prophylactically (2 mg/kg) or therapeutically (4 mg/kg). Treated mice showed accelerated body weight recovery, reduced lung viral load, and alleviated pulmonary pathology. Mechanistic analyses indicated that Nb74 neutralizes virus by blocking viral attachment to the host. Furthermore, combined hydrogen-deuterium exchange mass spectrometry (HDX-MS) with escape mutant analysis mapped its epitope to a conserved lateral patch on the HA1 subunit, consistent with a conformational epitope. Overall, these results demonstrate the therapeutic promise of intratracheally delivered Nb74 and provide insights for H7 AIVs vaccine design.

Source: 


Link: https://journals.asm.org/doi/10.1128/jvi.00563-26

____

Immunogenicity and safety of AS03-adjuvanted A/Astrakhan/3212/2020 #H5N8 -like #influenza #vaccine in adults: Phase 1/2, observer-blinded, randomized trial

 


ABSTRACT

Influenza pandemics arise from novel influenza A viruses. Recent emergence of a new clade (2.3.4.4.b) of the highly pathogenic H5N1 in animals and humans highlighted its pandemic potential. We evaluated the immunogenicity and safety of GSK’s AS03-adjuvanted H5N8 vaccine in adults. In this phase 1/2, observer-blinded, age-stratified, randomized trial, healthy US adults (age, ≥18 y) received two intramuscular doses of hemagglutinin antigen (3.75 or 7.50 μg) with AS03A or AS03B, administered 21 d apart. Immunogenicity – seroprotection rates (SPRs), seropositivity, geometric mean titers (GMTs), geometric mean fold rise (GMFR), and seroconversion rates (SCRs) – was evaluated on day 43 using hemagglutination inhibition (HI) and microneutralization (MN) assays. Safety was monitored throughout the study. Of 520 enrolled participants, 518 were vaccinated. On day 43, the US Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research criteria for influenza vaccines were met. HI SPRs, seropositivity rates, SCRs, GMTs, and GMFR appeared to be higher in the AS03A vs AS03B group. Immune responses were generally higher in younger (aged 18–64 y) vs older (aged ≥65 y) adults. Immune responses were also detected in MN assays, with a correlation between HI and MN responses on day 43 across age groups and vaccine formulations. Safety was acceptable, with no increase in adverse events post-dose 2. Reactogenicity appeared more common in younger adults. The antigen-sparing potential of AS03 was demonstrated, with an acceptable safety profile. The benefit/risk profile was favorable for all formulations tested, including 3.75 µg AS03A (licensed in the US).


ClinicalTrials.gov registration: NCT05975840.

Source: 


Link: https://www.tandfonline.com/doi/full/10.1080/21645515.2026.2649314

____

#Germany - #Influenza A #H5N1 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification

 


A flock of backyard laying hens in Bayern Region.

Source: 


Link: https://wahis.woah.org/#/in-review/7616

____

Thursday, June 11, 2026

#Risk of #Bundibugyo virus #transmission through #substances of #human origin in the #EU / EEA (ECDC, June 11 '26)

 


    11 June 2026

    The outbreak of Ebola disease caused by Bundibugyo virus (BDBV, Orthoebolavirus bundibugyoense), currently affecting the Democratic Republic of the Congo (DRC) and Uganda, draws attention to the potential risk of BDBV transmission via donated blood and blood components, cells, tissues and organs – i.e. substances of human origin (SoHO).


Background

    Ebola disease is caused by viruses in the Orthoebolavirus genus. Three orthoebolaviruses are known to cause large outbreaks: BDBV, Ebola virus (EBOV, previously known as Zaire ebolavirus), and Sudan virus (SUDV). 

    The typical incubation period for Ebola disease ranges from two to 21 days (mean: six days). 

    The prodromal phase lasts for up to 10 days, during which the infected individual experiences a sudden onset of flu-like illness. This is followed by progressive weakness, anorexia, diarrhoea, nausea, and vomiting. The next stage of the disease is characterised by gastrointestinal, neurological, vascular, cutaneous and respiratory symptoms. Haemorrhagic manifestations may also occur. During the final stage, patients may die from a combination of multi-organ failure and hypovolemic shock due to severe fluid loss. 


Key findings and recommendations

Risk assessment

    The overall risk of Bundibugyo virus transmission through substances of human origin (SoHO) in the European Union/European Economic Area (EU/EEA) is currently assessed as very low.


Recommendations

    ECDC recommends temporary deferral of asymptomatic individuals donating SoHO for at least six weeks after arriving from areas with Bundibugyo virus community transmission.

    In the context of the current Ebola disease outbreak, individuals who are being monitored due to contact with a patient with an infection, or other exposure to Bundibugyo virus are ineligible to donate SoHO for at least six weeks from the beginning of the monitoring period

    ECDC recommends a permanent deferral from donation of blood, cells and tissues for donors who have recovered from Ebola disease.

    ECDC recommends that individuals who have had sexual contact with persons who have recovered from Ebola disease should be deferred from donating SoHO for at least six weeks after exposure, irrespective of the time elapsed since the recovery of the convalescent sexual contact.

Source: 


Link: https://www.ecdc.europa.eu/en/publications-data/risk-bundibugyo-virus-transmission-through-substances-human-origin-european

____

#Andes #hantavirus #outbreak in cruise ship (ECDC, June 11 '26): 1 case reclassified from probable to confirmed

 


    This page is updated as more information becomes available. It was last updated 11 June at 13:05.


    On 2 May 2026, ECDC was notified of a cluster of severe respiratory illness on MV Hondius, a Dutch-flagged cruise ship with passengers and crew from 23 countries, including nine EU/EEA countries. 

    The virus has been identified as Andes hantavirus.

    As of 11 June 2026, 13 cases have been reported in total, including 12 confirmed and one probable case.

    Since the last update on 26 May 2026, one of the previously reported probable cases was reclassified as confirmed following positive laboratory result for hantavirus infection.

    The identification of additional cases after former passengers and crew returned to their home country is possible given the long incubation period of Andes hantavirus and the possibility that some infections occurred on board on the ship. 

    The risk to the EU/EEA general population remains very low.


    ° Confirmed cases12

    ° Probable cases1

    ° Suspected cases0

    ° Number of deaths3

(...)

Source: 


Link: https://www.ecdc.europa.eu/en/infectious-disease-topics/hantavirus-infection/surveillance-and-updates/andes-hantavirus-outbreak

____

My New Space

Most Popular Posts